Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models

Neuropharmacology

Volumn 59, Issue 4-5, 2010, Pages 353-357

  Choi Ji Kyung, J K ^a   Carreras, Isabel ^b,c   Dedeoglu, Alpaslan ^b,c   Jenkins, Bruce G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Magic angle spinning; MRS; Scyllo inositol; Transgenic mouse

Indexed keywords

GLUTAMINE; INOSITOL DERIVATIVE; SCYLLO INOSITOL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BRAIN LEVEL; FEMALE; FLUID INTAKE; FRONTAL CORTEX; HIGH RESOLUTION MAGIC ANGLE SPINNING; HIPPOCAMPUS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SIGNAL NOISE RATIO; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; PRESENILIN-1;

EID: 77956259428     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.03.011     Document Type: Article

References (24)

1. Brand A., Richter-Landsberg C., Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 1993, 15:289-298.
2. Choi J.K., Dedeoglu A., Jenkins B.G. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed. 2007, 20:216-237.
3. Choi J.K., Jenkins B.G., Carreras I., Kaymakcalan S., Cormier K., Kowall N.W., Dedeoglu A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. 2009, 10.1016/j.expneurol.2009.07.032.
4. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012:60-65.
5. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 1997, 56:321-339.
6. Fenili D., Brown M., Rappaport R., McLaurin J. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J. Mol. Med. 2007, 85:603-611.
7. Griffith H.R., den Hollander J.A., Stewart C.C., Evanochko W.T., Buchthal S.D., Harrell L.E., Zamrini E.Y., Brockington J.C., Marson D.C. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed. 2007, 20:709-716.
8. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
9. Isaacks R.E., Bender A.S., Kim C.Y., Shi Y.F., Norenberg M.D. Effect of ammonia and methionine sulfoximine on myo-inositol transport in cultured astrocytes. Neurochem. Res. 1999, 24:51-59.
10. Jenkins B.G., Klivenyi P., Kustermann E., Andreassen O.A., Ferrante R.J., Rosen B.R., Beal M.F. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74:2108-2119.
11. von Kienlin M., Kunnecke B., Metzger F., Steiner G., Richards J.G., Ozmen L., Jacobsen H., Loetscher H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 2005, 18:32-39.
12. Klunk W.E., Xu C., Panchalingam K., McClure R.J., Pettegrew J.W. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 1996, 17:349-357.
13. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U S A 2005, 102:11906-11910.
14. McLaurin J., Golomb R., Jurewicz A., Antel J.P., Fraser P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J. Biol. Chem. 2000, 275:18495-18502.
15. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12:801-808.
16. Michaelis T., Helms G., Merboldt K.D., Hanicke W., Bruhn H., Frahm J. Identification of Scyllo-inositol in proton NMR spectra of human brain in vivo. NMR Biomed. 1993, 6:105-109.
17. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
18. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., Laferla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006.
19. Pettegrew J.W., Klunk W.E., Panchalingam K., McClure R.J., Stanley J.A. Magnetic resonance spectroscopic changes in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1997, 826:282-306.
20. Seaquist E.R., Gruetter R. Identification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H- and 13C-NMR. Magn. Reson. Med. 1998, 39:313-316.
21. Shonk T.K., Moats R.A., Gifford P., Michaelis T., Mandigo J.C., Izumi J., Ross B.D. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995, 195:65-72. [see comments].
22. Spector R. The transport and metabolism of scyllo-inositol in the central nervous system. J. Neurochem. 1978, 31:1113-1115.
23. Thurston J.H., Sherman W.R., Hauhart R.E., Kloepper R.F. Myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr. Res. 1989, 26:482-485.
24. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 924:133-140.